Davidson MH - Search Results

1

Reducing residual risk for patients on statin therapy: the potential role of combination therapy.

Davidson MH. Davidson MH. Am J Cardiol. 2005 Nov 7;96(9A):3K-13K; discussion 34K-35K. doi: 10.1016/j.amjcard.2005.08.002. Epub 2005 Sep 12. Am J Cardiol. 2005. PMID: 16291008 Review.

2

Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy.

Polonsky TS, Davidson MH. Polonsky TS, et al. Among authors: davidson mh. Am J Cardiol. 2008 Apr 17;101(8A):27B-35B. doi: 10.1016/j.amjcard.2008.02.051. Am J Cardiol. 2008. PMID: 18375238 Review.

3

Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals.

Davidson MH, Nawrocki JW, Weiss SR, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM. Davidson MH, et al. Am J Cardiol. 1997 Aug 1;80(3):347-8. doi: 10.1016/s0002-9149(97)00360-3. Am J Cardiol. 1997. PMID: 9264433 Clinical Trial.

4

Safety of aggressive lipid management.

Davidson MH, Robinson JG. Davidson MH, et al. J Am Coll Cardiol. 2007 May 1;49(17):1753-62. doi: 10.1016/j.jacc.2007.01.067. Epub 2007 Apr 16. J Am Coll Cardiol. 2007. PMID: 17466224 Free article. Review.

5

Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.

Davidson MH. Davidson MH. Expert Opin Drug Saf. 2006 Jan;5(1):145-56. doi: 10.1517/14740338.5.1.145. Expert Opin Drug Saf. 2006. PMID: 16370963 Review.

6

Statin and ezetimibe combination therapy in cardiovascular disease.

Dembowski E, Davidson MH. Dembowski E, et al. Among authors: davidson mh. Curr Opin Endocrinol Diabetes Obes. 2009 Apr;16(2):183-8. doi: 10.1097/MED.0b013e3283295297. Curr Opin Endocrinol Diabetes Obes. 2009. PMID: 19262375 Review.

7

Combination therapy in the management of complex dyslipidemias.

Davidson MH, Toth PP. Davidson MH, et al. Curr Opin Lipidol. 2004 Aug;15(4):423-31. doi: 10.1097/01.mol.0000137221.16160.b9. Curr Opin Lipidol. 2004. PMID: 15243215 Review.

8

Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.

Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M; LCP-AtorFen Investigators. Davidson MH, et al. Clin Ther. 2009 Dec;31(12):2824-38. doi: 10.1016/j.clinthera.2009.12.007. Clin Ther. 2009. PMID: 20110022 Clinical Trial.

9

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, Black D. Davidson M, et al. Am J Cardiol. 1997 Jun 1;79(11):1475-81. doi: 10.1016/s0002-9149(97)00174-4. Am J Cardiol. 1997. PMID: 9185636 Clinical Trial.

10

Combination therapy for dyslipidemia: safety and regulatory considerations.

Davidson MH. Davidson MH. Am J Cardiol. 2002 Nov 20;90(10B):50K-60K. doi: 10.1016/s0002-9149(02)02970-3. Am J Cardiol. 2002. PMID: 12467940

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

365 results

Search Page